The Safety and Efficacy of Commercial BCMA-Directed CAR T-Cell Therapy in Systemic AL Amyloidosis With Concurrent Myeloma - PubMed
3 hours ago
- #CAR T-cell therapy
- #AL amyloidosis
- #Myeloma
- The study evaluates the safety and efficacy of commercial BCMA-directed CAR T-cell therapy in systemic AL amyloidosis with concurrent myeloma.
- The research focuses on patients with both AL amyloidosis and myeloma, assessing the therapeutic potential of CAR T-cell therapy targeting BCMA.
- Key areas of interest include the impact on cardiac amyloidosis and the use of chimeric antigen receptor T-cell technology.
- The findings are published with a DOI: 10.1002/ajh.70294 and PMID: 41862775.